# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Jon Young maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $16 to $15.
ALLR: 151% | Allarity Therapeutics shares are trading higher after the company announced that Stenoparib shows a clear clinical...
Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.46) by 21...
Piper Sandler analyst Jason Bednar reiterates Pulmonx (NASDAQ:LUNG) with a Overweight and maintains $17 price target.
Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatment...